- To review the role of alpha synuclein in the pathogenesis of Parkinson’s disease.
- To review various potential approaches targeting alpha synuclein as disease modifying therapies for Parkinson’s disease.
To summarize the current status of active clinical trials targeting alpha synuclein
Thursday, December 3, 2020 - 7:30am to 8:30am
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Anthony Lang, MD